The diverse functions of the PD1 inhibitory pathway
- PMID: 28990585
- DOI: 10.1038/nri.2017.108
The diverse functions of the PD1 inhibitory pathway
Abstract
T cell activation is a highly regulated process involving peptide-MHC engagement of the T cell receptor and positive costimulatory signals. Upon activation, coinhibitory 'checkpoints', including programmed cell death protein 1 (PD1), become induced to regulate T cells. PD1 has an essential role in balancing protective immunity and immunopathology, homeostasis and tolerance. However, during responses to chronic pathogens and tumours, PD1 expression can limit protective immunity. Recently developed PD1 pathway inhibitors have revolutionized cancer treatment for some patients, but the majority of patients do not show complete responses, and adverse events have been noted. This Review discusses the diverse roles of the PD1 pathway in regulating immune responses and how this knowledge can improve cancer immunotherapy as well as restore and/or maintain tolerance during autoimmunity and transplantation.
Similar articles
-
An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.J Recept Signal Transduct Res. 2018 Feb;38(1):31-36. doi: 10.1080/10799893.2017.1414843. Epub 2017 Dec 18. J Recept Signal Transduct Res. 2018. PMID: 29252078
-
Coinhibitory Pathways in Immunotherapy for Cancer.Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25. Annu Rev Immunol. 2016. PMID: 26927206 Review.
-
PDL-1/PD1 inhibitors: antibody or antinobody?Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23. Future Oncol. 2017. PMID: 28831825 No abstract available.
-
Immunotherapy for head and neck cancers: an update and future perspectives.Immunotherapy. 2019 May;11(7):561-564. doi: 10.2217/imt-2019-0022. Immunotherapy. 2019. PMID: 30943860 Review. No abstract available.
-
[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14. Rev Pneumol Clin. 2015. PMID: 25687821 Review. French.
Cited by
-
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).Oncoimmunology. 2022 Oct 5;11(1):2127691. doi: 10.1080/2162402X.2022.2127691. eCollection 2022. Oncoimmunology. 2022. PMID: 36211807 Free PMC article.
-
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.Cell Commun Signal. 2023 Nov 9;21(1):321. doi: 10.1186/s12964-023-01289-9. Cell Commun Signal. 2023. PMID: 37946301 Free PMC article. Review.
-
IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion.Cancer Cell Int. 2024 Feb 7;24(1):60. doi: 10.1186/s12935-024-03234-3. Cancer Cell Int. 2024. PMID: 38326861 Free PMC article.
-
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.Eur Radiol. 2021 Apr;31(4):1853-1862. doi: 10.1007/s00330-020-07249-y. Epub 2020 Sep 30. Eur Radiol. 2021. PMID: 32995974 Free PMC article. Clinical Trial.
-
Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions.Explor Target Antitumor Ther. 2022;3(5):598-629. doi: 10.37349/etat.2022.00103. Epub 2022 Oct 27. Explor Target Antitumor Ther. 2022. PMID: 36338519 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials